A major difference in RET inhibition found between pralsetinib and selpercatinib

Pralsetinib and selpercatinib were recently approved for RET-targeted cancer therapy. However, it was unclear whether pralsetinib and selpercatinib have different activity. We found that the RET roof L730I/V mutants are strongly resistant to pralsetinib but remain sensitive to selpercatinib.
Published in Cancer
A major difference in RET inhibition found between pralsetinib and selpercatinib

Share this post

Choose a social network to share with, or copy the shortened URL to share elsewhere

This is a representation of how your post may appear on social media. The actual post will vary between social networks

The oncogenic RET kinase was initially targeted with multikinase inhibitors, such as cabozantinib and vandetanib. These inhibitors were originally developed to inhibit other protein tyrosine kinases, but cross-inhibit RET. In the last few years, two highly potent and selective RET protein tyrosine kinase inhibitors (TKIs), selpercatinib (LOXO-292) and pralsetinib (BLU-667), were developed. These potent and selective RET inhibitors gave improved response rates in RET-altered cancers and the responses were more durable, leading to approval by US Food and Drug Administration in late 2020 for treating RET-altered non-small cell lung cancer (NSCLC) and thyroid cancers. However, it was unclear whether these two drugs have different activity.

One lesson learned from kinase-targeted cancer therapies was that resistance would eventually emerge. The resistance might occur through acquired secondary mutations on the targeted kinases or through activation of alternative driver oncogenes. The mechanism of drug-adapted target mutations could be circumvented by developing new drugs capable of inhibiting the mutant kinases. This was exemplified by EGFR mutant- and ALK fusion-targeted therapies in NSCLC.

Acquired drug-resistant mutations were often discovered through analysis of tumor tissues or cell-free DNAs (cfDNAs) when diseases progressed after the initial response. For TKIs that give more depth and durable responses, this reactive approach could require a prolonged time to identify the resistant mutants and then develop the new drugs to inhibit these mutants. Using a proactive approach to accelerate the discovery of pralsetinib- and/or selpercatinib-resistant RET kinase mutants, we screened the randomly mutated KIF5B-RET oncogene for pralsetinib- or selpercatinib-resistant mutants, and cross-profiled their sensitivities1,2. Data obtained so far showed that all selpercatinib-resistant mutants were also resistant to pralsetinib. The G810R/C/S substitutions displayed the strongest resistance1. No V804M/L gatekeeper mutants were found. In fact, tumors with the RET V804M mutant responded to selpercatinib1. Co-crystal structures showed that selpercatinib and pralsetinib use a binding mode that does not penetrate the gate in the RET kinase domain1. G810 is located on the floor (C-lobe) of the solvent-front region of the drug-binding pocket in the kinase domain. The acquired G810 solvent-front mutations have been reported recently in several clinical studies.

Isolation and characterization of pralsetinib-resistant RET mutants identified L730V/I as mutants that had ~60-fold higher IC50 to pralsetinib2. The extent of pralsetinib resistance by the L730V/I mutants was comparable to those of the G810C/S mutants (40 to 70-fold higher IC50). L730 is located at the roof (N-lobe) of the solvent-front area. L730 was not in the coverage region of the RET oncogene in some cfDNA assays1. Therefore, L730 mutations might have evaded detection by some cfDNA assays. A recent study using a cfDNA assay that covered the entire RET coding region found acquired L730V and T729_L730insL mutations in patients with pralsetinib-resistant NSCLC3. Thus, L730 roof mutations have been validated in patients with acquired pralsetinib-resistant tumors.

Interestingly, the effects of L730V/I mutants on selpercatinib (4 to 7-fold higher IC50) were smaller than that of the V804M mutant (17-fold higher IC50). Consistently, in vivo experiments in animals showed that the growth of BaF3/KIF5B-RET(L730V/I) cell-derived tumors could not be inhibited by pralsetinib, whereas they were readily inhibited by selpercatinib2. Thus, we have found an important difference between pralsetinib and selpercatinib. Our finding points to selpercatinib as a readily available option for continuing suppression of RET-driven tumors when L730V/I roof mutations are detected in patients whose tumors progress on pralsetinib treatment.


  1. Subbiah, V., Shen, T., Terzyan, S. S., Liu, X., Hu, X. et al. Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations. Ann Oncol 32, 261-268 (2021).
  2. Shen, T., Hu, X., Liu, X., Subbiah, V., Mooers, B. H. M. et al. The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib. npj Precis Onc 5, 48 (2021). doi: 10.1038/s41698-021-00188-x
  3. Gainor, J., Curigliano, G., Doebele, R. C., Lin, J. J., Ou, S. H. et al. Analysis of resistance mechanisms to pralsetinib in patients with RET fusion-positive non-small cell lung cancer (NSCLC) from the ARROW study. IASLC 2020 North American Conference on Lung Cancer (October 16-17, 2020), Abstract OA05.02 (2020).

Please sign in or register for FREE

If you are a registered user on Research Communities by Springer Nature, please sign in

Go to the profile of Asiah K Ghosh
almost 3 years ago


Subscribe to the Topic

Cancer Biology
Life Sciences > Biological Sciences > Cancer Biology

Related Collections

With collections, you can get published faster and increase your visibility.

AI in precision oncology

This Collection is a partnership between npj Precision Oncology and npj Breast Cancer. It will bring together articles on all facets of AI in cancer research.

Publishing Model: Open Access

Deadline: Apr 19, 2024

Innovations in cancers of the central nervous system

This Collection invites research on tumors involving the central nervous system, including primary glial tumors, meningiomas and metastatic tumors in adults.

Publishing Model: Open Access

Deadline: Mar 01, 2024